Legend Biotech CARVYKTI Sales Hit $186M
Ticker: LEGN · Form: 6-K · Filed: Jul 17, 2024 · CIK: 1801198
| Field | Detail |
|---|---|
| Company | Legend Biotech Corp (LEGN) |
| Form Type | 6-K |
| Filed Date | Jul 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $186 million |
| Sentiment | bullish |
Sentiment: bullish
Topics: sales-update, collaboration, pharmaceutical
TL;DR
Legend Biotech's CARVYKTI® pulled in $186M last quarter, good news for the stock.
AI Summary
Legend Biotech Corporation announced on July 17, 2024, that its drug CARVYKTI® generated approximately $186 million in net trade sales for the quarter ended June 30, 2024. This figure is based on information provided by Janssen Biotech, Inc., pursuant to their collaboration agreement.
Why It Matters
This sales figure provides insight into the market performance and adoption of CARVYKTI®, a key product for Legend Biotech, impacting investor confidence and future revenue projections.
Risk Assessment
Risk Level: low — This is a routine sales update and does not introduce new risks.
Key Numbers
- $186 million — CARVYKTI® Net Trade Sales (Sales for the quarter ended June 30, 2024)
Key Players & Entities
- Legend Biotech Corporation (company) — Filer and seller of CARVYKTI®
- CARVYKTI® (product) — Drug generating sales
- Janssen Biotech, Inc. (company) — Collaborator providing sales data
- $186 million (dollar_amount) — Net trade sales for CARVYKTI®
- June 30, 2024 (date) — End of the sales reporting quarter
- July 17, 2024 (date) — Date of the announcement
FAQ
What was the total net trade sales for CARVYKTI® in the quarter ended June 30, 2024?
CARVYKTI® generated approximately $186 million in net trade sales for the quarter ended June 30, 2024.
Who provided the sales data for CARVYKTI® to Legend Biotech?
Janssen Biotech, Inc. provided the sales data to Legend Biotech.
What is the relationship between Legend Biotech and Janssen Biotech regarding CARVYKTI®?
They have a Collaboration and License Agreement dated December 21, 2017.
On what date was this sales announcement made?
The announcement was made on July 17, 2024.
What form type is this SEC filing?
This is a Form 6-K filing.
Filing Stats: 728 words · 3 min read · ~2 pages · Grade level 18.5 · Accepted 2024-07-17 07:30:55
Key Financial Figures
- $186 million — CARVYKTI ® generated approximately $186 million in net trade sales during the quarter e
Filing Documents
- f6k_071724.htm (6-K) — 14KB
- 0001171843-24-003984.txt ( ) — 15KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LEGEND BIOTECH CORPORATION Date: July 17, 2024 By: /s/ Ying Huang Name: Ying Huang, Ph.D. Title: Chief Executive Officer